Maxim Group initiated coverage on Nuvectis Pharma with a new price target
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/2/2025 | $17.00 | Buy | Maxim Group |
| 3/17/2025 | $19.00 | Buy | Laidlaw |
| 7/13/2022 | $21.00 | Buy | Ladenburg Thalmann |
| 3/2/2022 | $14.00 | Buy | HC Wainwright & Co. |
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4/A - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)
SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4/A - Nuvectis Pharma, Inc. (0001875558) (Issuer)
4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)
Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00
Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00
Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00
Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event3rd Annual H.C. Wainwright BioConnect Investor ConferenceDateMay 20th, 2025Time10:30 – 11:00 a.m. ETLinkNuvectis Pharma Presentation Webcast Link About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on
NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategyCompleted $15.5M financing, extending projected cash runway into 1Q2027 FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, tod
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted cancers and in combination with market leading therapies to overcome resistance in NSCLC Fort Lee, NJ, April 29, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innova
8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)
424B5 - Nuvectis Pharma, Inc. (0001875558) (Filer)
10-Q - Nuvectis Pharma, Inc. (0001875558) (Filer)